Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transriptome profiling of mutant p53 skin deficient in AURORA-A KINASE

ABSTRACT: We performed next-generation sequencing of RNA to determine the transcriptional changes in hyperplastic mutant p53 skin after the epithelial deletion of the AURORA-A Kinase gene in mice.

ORGANISM(S): Mus musculus

PROVIDER: GSE106281 | GEO | 2018/10/30

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Transriptome profiling of mutant p53 skin deficient in AURORA-A KINASE

Project description:Transriptome profiling of mutant p53 skin deficient in AURORA-A KINASE

| PRJNA416114 | ENA

CGH Analysis of Murine Squamous Cell Carcinoma: Control vs. Tumors overexpressing Aurora Kinase A

Project description:Genomic alterationsin murine skin Squamous Cell Carcinoma(SCC) generated were analyzed from mice that expressed human Aurora Kinase A under control of Keratin 14 driven and RU486 inducible GLP65 activator protein. Monogenic GLP65 (control) and bigenic GLP65; Aurora-A mice were treated with DMBA once and thrice per week with TPA and RU486 to generate SCCs.

2010-05-27 | GSE16342 | GEO

Aurora kinase A is upregulated in cutaneous T-cell lymphoma and represents a potential therapeutic target

Project description:Cutaneous T-cell lymphomas form a heterogeneous group of non-Hodgkin lymphomas characterized by only poor prognosis in advanced stage. Despite significant progress made in the identification of novel genes and pathways involved in the pathogenesis of cutaneous lymphoma, the therapeutic value of these findings has still to be proven. Here, we demonstrate by gene expression arrays that aurora kinase A is one of highly overexpressed genes of the serine/threonine kinase in CTCL. The finding was confirmed by qualitative RT-PCR, Western blotting and immunohistochemistry in CTCL cell lines and primary patient samples. Moreover, treatment with a specific aurora kinase A inhibitor blocks cell proliferation by inducing cell cycle arrest in G2 phase as well as apoptosis in CTCL cell lines. These new data provide a promising rationale for using aurora kinase A inhibition as a therapeutic modality of CTCL. 14 lesional skin biopsies of different MF patients (patch=3, plaque=6, tumor=4) and 9 healthy controls. Comparison between Cutaneus Tcell Lymphoma Samples and Healthy Control Tissue

2015-03-31 | E-GEOD-59307 | biostudies-arrayexpress

Expression profiling, U2OS, Aurora kinase and p38 inhibitor response

Project description:U-2 OS (human osteosarcoma cell line) were treated with ZM447439 (an aurora kinase inhibitor), SB202190 (a p38 inhibitor) or ZM447439+SB202190 and resulting changes in gene expression were profiled.

2017-07-01 | E-MTAB-1210 | biostudies-arrayexpress

Ablation of casein kinase 1 in keratinocytes induces p53-dependent hyperpigmentation of the skin

Project description:To characterize the role of CK1 (encoded by Csnk1a1) in skin physiology, we crossed mice with floxed Csnk1a1 with mice expressing K14CreERT2 to generate mice in which tamoxifen induces the deletion of Csnk1a1 exclusively in keratinocytes (SKO). In addition, we established K14CreERT2 CK1/p53 double-knockout (DKO) to analyze the effect of coablation of both genes. 4-hydroxy-Tamoxifen was applied for 14 days to induce the deletion of CK1 and/or p53 in the epidermis of the mice. In addition, wild type mice where exposed to UVB irradiation to compare the effect of CK1a ablation with the effects of normal UV exposure. In comparison, we analyzed also wild type mice as reference. RNA was obtained from cells derived from mouse ear dorsal-epidermis and tail skin. Subsequently, we performed RNA sequencing and transcriptome analysis.

2017-08-25 | E-MTAB-5442 | biostudies-arrayexpress

Transcriptional pathway signatures for the Aurora inhibitor Danusertib

Project description:Treatment with Aurora inhibitors has been shown to induce diverse biological responses in different tumor cell lines, in part depending on their p53 status. To characterize at the transcriptional level the effects of Danusertib we analyzed by microarray different tumor cell lines, with WT or mutant p53 status, that showed differential cell cycle response upon drug treatment. We analyzed the effects of Danusertib treatment in different tumor cell lines derived from ovary (A2780, p53WT), breast (MCF-7, p53WT and MDA-MB-468, p53 mut) and colon carcinoma (HCT116, p53 WT and Colo205, p53 mut). Cell line were treated (TRT) or left unreated (CTRL) for 24 hrs with 1 uM Danusertib.

2011-09-19 | E-GEOD-24547 | biostudies-arrayexpress

CHD1 Alters Sensitivity to Aurora Kinase A Inhibitors

Project description:In this study, we sought to understand the impact of CHD1 on sensitivity to Aurora A inhibitors in prostate and other cancers and underlying mechanisms

2023-10-16 | GSE186633 | GEO

Transcriptional pathway signatures for the Aurora inhibitor Danusertib

2011-09-20 | GSE24547 | GEO

Lysine succinylome in human skin

Project description:The data present lysine succinylome in normal skin and hyperplastic scar

2024-02-28 | PXD050207 | iProX

Expression analysis of zebrafish melanoma and skin from the mitf-BRAFV600E;p53-/- line

Project description:Investigation of expression differences between skin and melanomas from a transgenic BRAFV600E zebrafish model of melanoma The embryos described in this study are further analyzed in a manuscript submitted for publication by White, et al. A 15 chip study using RNA extracted from either WT zebrafish skin, mitf-BRAFV600E;p53-/- skin or mitf-BRAFV600E;p53-/- melanoma

2011-03-30 | E-GEOD-24528 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data